107 related articles for article (PubMed ID: 15555210)
1. A phase II trial of ISIS 3521 in patients with metastatic colorectal cancer.
Marshall JL; Eisenberg SG; Johnson MD; Hanfelt J; Dorr FA; El-Ashry D; Oberst M; Fuxman Y; Holmlund J; Malik S
Clin Colorectal Cancer; 2004 Nov; 4(4):268-74. PubMed ID: 15555210
[TBL] [Abstract][Full Text] [Related]
2. Phase II randomized study of ISIS 3521 and ISIS 5132 in patients with locally advanced or metastatic colorectal cancer: a National Cancer Institute of Canada clinical trials group study.
Cripps MC; Figueredo AT; Oza AM; Taylor MJ; Fields AL; Holmlund JT; McIntosh LW; Geary RS; Eisenhauer EA
Clin Cancer Res; 2002 Jul; 8(7):2188-92. PubMed ID: 12114419
[TBL] [Abstract][Full Text] [Related]
3. A phase I trial of c-Raf kinase antisense oligonucleotide ISIS 5132 administered as a continuous intravenous infusion in patients with advanced cancer.
Cunningham CC; Holmlund JT; Schiller JH; Geary RS; Kwoh TJ; Dorr A; Nemunaitis J
Clin Cancer Res; 2000 May; 6(5):1626-31. PubMed ID: 10815879
[TBL] [Abstract][Full Text] [Related]
4. Phase I clinical/pharmacokinetic and pharmacodynamic trial of the c-raf-1 antisense oligonucleotide ISIS 5132 (CGP 69846A).
Stevenson JP; Yao KS; Gallagher M; Friedland D; Mitchell EP; Cassella A; Monia B; Kwoh TJ; Yu R; Holmlund J; Dorr FA; O'Dwyer PJ
J Clin Oncol; 1999 Jul; 17(7):2227-36. PubMed ID: 10561280
[TBL] [Abstract][Full Text] [Related]
5. Phase I Trial of ISIS 5132, an antisense oligonucleotide inhibitor of c-raf-1, administered by 24-hour weekly infusion to patients with advanced cancer.
Rudin CM; Holmlund J; Fleming GF; Mani S; Stadler WM; Schumm P; Monia BP; Johnston JF; Geary R; Yu RZ; Kwoh TJ; Dorr FA; Ratain MJ
Clin Cancer Res; 2001 May; 7(5):1214-20. PubMed ID: 11350886
[TBL] [Abstract][Full Text] [Related]
6. A randomized phase II and pharmacokinetic study of the antisense oligonucleotides ISIS 3521 and ISIS 5132 in patients with hormone-refractory prostate cancer.
Tolcher AW; Reyno L; Venner PM; Ernst SD; Moore M; Geary RS; Chi K; Hall S; Walsh W; Dorr A; Eisenhauer E
Clin Cancer Res; 2002 Aug; 8(8):2530-5. PubMed ID: 12171880
[TBL] [Abstract][Full Text] [Related]
7. Phase I study of an antisense oligonucleotide to protein kinase C-alpha (ISIS 3521/CGP 64128A) in patients with cancer.
Yuen AR; Halsey J; Fisher GA; Holmlund JT; Geary RS; Kwoh TJ; Dorr A; Sikic BI
Clin Cancer Res; 1999 Nov; 5(11):3357-63. PubMed ID: 10589745
[TBL] [Abstract][Full Text] [Related]
8. Phase I evaluation of ISIS 3521, an antisense oligodeoxynucleotide to protein kinase C-alpha, in patients with advanced cancer.
Nemunaitis J; Holmlund JT; Kraynak M; Richards D; Bruce J; Ognoskie N; Kwoh TJ; Geary R; Dorr A; Von Hoff D; Eckhardt SG
J Clin Oncol; 1999 Nov; 17(11):3586-95. PubMed ID: 10550158
[TBL] [Abstract][Full Text] [Related]
9. Phase II study of CGP 69846A (ISIS 5132) in recurrent epithelial ovarian cancer: an NCIC clinical trials group study (NCIC IND.116).
Oza AM; Elit L; Swenerton K; Faught W; Ghatage P; Carey M; McIntosh L; Dorr A; Holmlund JT; Eisenhauer E;
Gynecol Oncol; 2003 Apr; 89(1):129-33. PubMed ID: 12694666
[TBL] [Abstract][Full Text] [Related]
10. Phase I clinical and pharmacokinetic study of protein kinase C-alpha antisense oligonucleotide ISIS 3521 administered in combination with 5-fluorouracil and leucovorin in patients with advanced cancer.
Mani S; Rudin CM; Kunkel K; Holmlund JT; Geary RS; Kindler HL; Dorr FA; Ratain MJ
Clin Cancer Res; 2002 Apr; 8(4):1042-8. PubMed ID: 11948111
[TBL] [Abstract][Full Text] [Related]
11. c-raf-1 depletion and tumor responses in patients treated with the c-raf-1 antisense oligodeoxynucleotide ISIS 5132 (CGP 69846A).
O'Dwyer PJ; Stevenson JP; Gallagher M; Cassella A; Vasilevskaya I; Monia BP; Holmlund J; Dorr FA; Yao KS
Clin Cancer Res; 1999 Dec; 5(12):3977-82. PubMed ID: 10632328
[TBL] [Abstract][Full Text] [Related]
12. Phase II trial with ISIS 5132 in patients with small-cell (SCLC) and non-small cell (NSCLC) lung cancer. A European Organization for Research and Treatment of Cancer (EORTC) Early Clinical Studies Group report.
Coudert B; Anthoney A; Fiedler W; Droz JP; Dieras V; Borner M; Smyth JF; Morant R; de Vries MJ; Roelvink M; Fumoleau P;
Eur J Cancer; 2001 Nov; 37(17):2194-8. PubMed ID: 11677106
[TBL] [Abstract][Full Text] [Related]
13. A Phase II trial of aprinocarsen, an antisense oligonucleotide inhibitor of protein kinase C alpha, administered as a 21-day infusion to patients with advanced ovarian carcinoma.
Advani R; Peethambaram P; Lum BL; Fisher GA; Hartmann L; Long HJ; Halsey J; Holmlund JT; Dorr A; Sikic BI
Cancer; 2004 Jan; 100(2):321-6. PubMed ID: 14716767
[TBL] [Abstract][Full Text] [Related]
14. ISIS-3521. Isis Pharmaceuticals.
Li K; Zhang J
Curr Opin Investig Drugs; 2001 Oct; 2(10):1454-61. PubMed ID: 11890365
[TBL] [Abstract][Full Text] [Related]
15. Absence of efficacy of subcutaneous antisense ICAM-1 treatment of chronic active Crohn's disease.
Schreiber S; Nikolaus S; Malchow H; Kruis W; Lochs H; Raedler A; Hahn EG; Krummenerl T; Steinmann G;
Gastroenterology; 2001 May; 120(6):1339-46. PubMed ID: 11313303
[TBL] [Abstract][Full Text] [Related]
16. Phase II study of ISIS 3521, an antisense oligodeoxynucleotide to protein kinase C alpha, in patients with previously treated low-grade non-Hodgkin's lymphoma.
Rao S; Watkins D; Cunningham D; Dunlop D; Johnson P; Selby P; Hancock BW; Fegan C; Culligan D; Schey S; Morris TC; Lissitchkov T; Oliver JW; Holmlund JT
Ann Oncol; 2004 Sep; 15(9):1413-8. PubMed ID: 15319248
[TBL] [Abstract][Full Text] [Related]
17. ISIS 2302. INXC ICAM1, Oligo-TCS.
Drugs R D; 1999 Jan; 1(1):85-6. PubMed ID: 10565996
[No Abstract] [Full Text] [Related]
18. Phase I and phase II safety and efficacy trial of intercellular adhesion molecule-1 antisense oligodeoxynucleotide (ISIS 2302) for the prevention of acute allograft rejection.
Kahan BD; Stepkowski S; Kilic M; Katz SM; Van Buren CT; Welsh MS; Tami JA; Shanahan WR
Transplantation; 2004 Sep; 78(6):858-63. PubMed ID: 15385805
[TBL] [Abstract][Full Text] [Related]
19. ISIS 2302. Oligo-TCS.
Drugs R D; 1999 Mar; 1(3):265-7. PubMed ID: 10566042
[No Abstract] [Full Text] [Related]
20. Double blind, placebo controlled trial of the remission inducing and steroid sparing properties of an ICAM-1 antisense oligodeoxynucleotide, alicaforsen (ISIS 2302), in active steroid dependent Crohn's disease.
Yacyshyn BR; Chey WY; Goff J; Salzberg B; Baerg R; Buchman AL; Tami J; Yu R; Gibiansky E; Shanahan WR;
Gut; 2002 Jul; 51(1):30-6. PubMed ID: 12077088
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
